Neural Stem Cell-based Cell Carriers Enhance Therapeutic Efficacy of an Oncolytic Adenovirus in an Orthotopic Mouse Model of Human Glioblastoma

被引：90

作者：

Ahmed, Atique U. ^{[1
]}

Thaci, Bart ^{[1
]}

Alexiades, Nikita G. ^{[1
]}

Han, Yu ^{[1
]}

Qian, Shuo ^{[1
]}

Liu, Feifei ^{[1
]}

Balyasnikova, Irina V. ^{[1
]}

Ulasov, Ilya Y. ^{[1
]}

Aboody, Karen S. ^{[2
,3
]}

Lesniak, Maciej S. ^{[1
]}

机构：

[1] Univ Chicago, Brain Tumor Ctr, Chicago, IL 60637 USA

[2] City Hope Natl Med Ctr, Dept Neurosci, Duarte, CA 91010 USA

[3] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA

来源：

MOLECULAR THERAPY | 2011年 / 19卷 / 09期

关键词：

GENE-THERAPY; MULTIPLE-SCLEROSIS; MALIGNANT GLIOMA; PROGENITOR CELLS; MIGRATION; DISEASE; BRAIN; NEUROBLASTOMA; REPLICATION; EXPRESSION;

D O I：

10.1038/mt.2011.100

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The potential utility of oncolytic adenoviruses as anticancer agents is significantly hampered by the inability of the currently available viral vectors to effectively target micrometastatic tumor burden. Neural stem cells (NSCs) have the ability to function as cell carriers for targeted delivery of an oncolytic adenovirus because of their inherent tumor-tropic migratory ability. We have previously reported that in vivo delivery of CRAd-S-pk7, a glioma-restricted oncolytic adenovirus, can enhance the survival of animals with experimental glioma. In this study, we show that intratumoral delivery of NSCs loaded with the CRAD-S-pk7 in an orthotopic xenograft model of human glioma is able to not only inhibit tumor growth but more importantly to increase median survival by similar to 50% versus animals treated with CRAd-S-pk7 alone (P = 0.0007). We also report that oncolytic virus infection upregulates different chemoattractant receptors and significantly enhances migratory capacity of NSCs both in vitro and in vivo. Our data further suggest that NSC-based carriers have the potential to improve the clinical efficacy of antiglioma virotherapy by not only protecting therapeutic virus from the host immune system, but also amplifying the therapeutic payload selectively at tumor sites.

引用

页码：1714 / 1726

页数：13

共 32 条

[31] Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy [J].

Willmon, Candice ;

Harrington, Kevin ;

Kottke, Timothy ;

Prestwich, Robin ;

Melcher, Alan ;

Vile, Richard .

MOLECULAR THERAPY, 2009, 17 (10) :1667-1676

[32]

Woiciechowsky C, 2004, MED SCI MONITOR, V10, pBR325

← 1 2 3 4 →